Drug Name: Vivjoa

Active Ingredient: oteseconazole

Indications: To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential

Approval Date: 4/26/2022

Company: Mycovia Pharmaceuticals, Inc

Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *